** Shares of medical equipment maker Revvity RVTY.N fall 5.4% to $93.5 premarket
** Co reports Q3 revenue of $699 mln, lower than analysts' estimates of $700.5 mln – LSEG data
** Co reports Q3 adj. profit of $1.18/shr vs analysts' average estimate of $1.14/shr – LSEG data
** RVTY reaffirms 2–4% organic growth; raises annual adj. EPS forecast to $4.90-$5.00 from prior view of $4.85-$4.95
** Board approves new $1 bln share buyback program, replacing prior plan, which was announced in October 2024– RVTY
** Up to last close, stock down 11.4% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))